Significantly reduced 24-hour urinary albumin excretion rate (24-hour UAE) and creatinine elevation rate, delayed progression to end-stage renal disease, with no significant impact on the incidence of renal-related adverse events or renal-related mortality. This evidence concerns the gene ALB and stage 5 chronic kidney disease.